Home » Investors » Press Releases » Invitation to the presentation of BICO’s interim report Q3, 2024

Single Press release

Invitation to the presentation of BICO’s interim report Q3, 2024

November 5, 2024 7:00 am

BICO’s Interim report for Q3 2024 will be published on Tuesday November 26, 2024, at 07:00am CET. Following the release of the report, a telephone conference with the opportunity to ask questions will be held in English at 10:00 am CET on the same day, with President & CEO Maria Forss and CFO Jacob Thordenberg presenting the report.

Information about the presentation and webcast
The presentation will be available on BICO’s website from 09:00am CET.
https://bico.com/investors/

If you wish to participate via webcast, please use the link below. https://ir.financialhearings.com/bico-q3-report-2024

If you wish to participate via teleconference, please register via the link below.
After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via teleconference. 
https://conference.financialhearings.com/teleconference/?id=50049741

For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com

The information was submitted for publication, through the agency of the contact person set out above, on November 5, 2024 at 7am CET.

For inquires related to the presentation or teleconference or if you wish to send questions to the speakers, please contact BICO Investor Relations.
Phone: +46 735 46 57 77
E-mail: ir@bico.com

BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments
Invitation to the presentation of BICO’s interim report Q3, 2024

Invitation to the presentation of BICO’s interim report Q3, 2024
Financials
Governance
The Share
News
Subscribe and stay updated with the latest news!
Subscribe
Copyright © 2024 BICO - The Bio Convergence Company - All rights reserved.

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.